SANDERLING MANAGEMENT COMPANY, LLC
SANDERLING MANAGEMENT COMPANY, LLC is a Seed, Series A, Series B and Series C+ fund in the US and Canada writing $1M–$100M checks into Healthcare, biomedical, therapeutics, biologics, vaccines, drug-delivery, platform-technologies, medical-devices, diagnostics and ehealth.
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- Healthcare, biomedical, therapeutics, biologics, vaccines, drug-delivery, platform-technologies, medical-devices, diagnostics, ehealth
- Check size
- $1M–$100M
- Invests in
- US-wide, Canada
- Actively investing
- Yes
- Founded
- 1979
Thesis
Sanderling Ventures, established in 1979, is a venture capital firm with a strong focus on the biomedical sector. Their investment thesis revolves around building new biomedical companies through active management and long-term partnerships with entrepreneurs. They target innovative technologies with multiple product applications, particularly in the early stages of development, with specializations in small molecule therapeutics, biologics and vaccines, drug delivery, platform technologies, medical devices, diagnostics, and digital/eHealth. They aim to support companies through later-stage financing to mitigate excessive dilution. The firm's geographic scope primarily includes the United States and Canada. While specific fund sizes are not detailed, Sanderling has a substantial investment history, having supported over 90 biomedical companies since its inception. Their typical check size per investment deal ranges from $1 million to $100 million.
Common questions
Does SANDERLING MANAGEMENT COMPANY, LLC invest at the Seed stage?
Yes. SANDERLING MANAGEMENT COMPANY, LLC lists Seed, Series A, Series B and Series C+ among the stages it invests in.
What check size does SANDERLING MANAGEMENT COMPANY, LLC write?
SANDERLING MANAGEMENT COMPANY, LLC writes $1M–$100M checks.
Where does SANDERLING MANAGEMENT COMPANY, LLC invest?
SANDERLING MANAGEMENT COMPANY, LLC invests in the US and Canada.